SGLT2 breast expression could affect the cardiovascular performance in pre-menopausal women with fatty vs. non fatty breast via over-inflammation and sirtuins' down regulation

Article Endocrinology & Metabolism

Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts

Raffaele Marfella et al.

Summary: The early pathogenesis of human diabetic cardiomyopathy is associated with overexpression of JunD/PPAR-gamma and lipid accumulation, which can be attenuated by treatment with SGLT2 inhibitors in diabetic patients.

METABOLISM-CLINICAL AND EXPERIMENTAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

Pasquale Paolisso et al.

Summary: The study found that type 2 diabetic AMI patients receiving SGLT2-I exhibited significantly reduced inflammatory response and smaller infarct size compared to those receiving other OAD agents.

CARDIOVASCULAR DIABETOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of 3 months of treatment with empagliflozin on left ventricle global longitudinal strain and myocardial mechano-energetic effiency

Ibrahim Etem Dural et al.

Summary: In patients with diabetes but no cardiovascular disease, the use of Empagliflozin for 3 months led to significant increases in left ventricular GLS and MME efficiency, indicating an improvement in cardiac pump efficiency and contraction.

ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes

Raffaele Marfella et al.

Summary: The study focused on investigating SGLT2 expression in human cardiomyocytes, revealing higher levels in diabetic patients compared to non-diabetic patients.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Impact of Sex Differences in Incident and Recurrent Coronary Events and All-Cause Mortality

Celestino Sardu et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pre-Menopausal Breast Fat Density Might Predict MACE During 10 Years of Follow-Up The BRECARD Study

Celestino Sardu et al.

Summary: This study found that pre-menopausal women with higher levels of adipose tissue in breast gland (lowest breast density, category A) had higher rates of MACES. Further clinical trials are needed to translate these results into clinical practice.

JACC-CARDIOVASCULAR IMAGING (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiac Energy Metabolism in Heart Failure

Gary D. Lopaschuk et al.

Summary: Changes in cardiac energy metabolism are complex and depend on the severity and type of heart failure, as well as the presence of common comorbidities such as obesity and type 2 diabetes. The failing heart experiences an energy deficit due to decreased mitochondrial oxidative capacity, compensated for by increased ATP production from glycolysis. Alterations in mitochondrial ATP production fuels and fatty acid oxidation contribute to the inefficiency of the failing heart, with potential therapeutic targets in energy metabolic pathways to improve cardiac function.

CIRCULATION RESEARCH (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up

Celestino Sardu et al.

Summary: T2DM patients using SGLT2-I under MiECC showed significantly reduced inflammatory burden and improved clinical outcomes at 5-year follow-up post-CABG.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment

Nunzia D'Onofrio et al.

Summary: The study demonstrated that SGLT2 inhibitors have a positive regulatory effect on atherosclerotic plaques in diabetic patients, showing significant improvements in inflammation and oxidative stress. Patients without diabetes had significantly higher overall survival from MACE at 2-year follow-up, while diabetic patients using SGLT2 inhibitors had a significantly lower rate of MACE over 2 years compared to non-users.

MOLECULAR METABOLISM (2021)

添加到收藏夹

Article Cell Biology

SIRT5 Inhibition Induces Brown Fat-Like Phenotype in 3T3-L1 Preadipocytes

Francesca Molinari et al.

Summary: The inhibition of SIRT5 stimulates brown adipogenesis in vitro, promoting the expression of brown adipocyte and mitochondrial markers and increasing lipolysis. This approach shows potential as a strategy to target obesity and type 2 diabetes by activating brown adipose tissue.

CELLS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction

Celestino Sardu et al.

Summary: The study found that PDM patients had higher levels of inflammation in pericoronary fat, while metformin therapy could potentially reduce inflammatory parameters, SGLT2, and leptin levels, and improve SIRT6 levels.

BIOMEDICINES (2021)

添加到收藏夹

Review Medicine, Research & Experimental